About
Now more than ever, the ability to successfully collaborate is a critical competency for pharmaceutical and biotech companies. With millions of dollars in future revenue at stake - and in some cases a company's survival - it is imperative that you, as counsel to or executive for a pharmaceutical or biotech company, have an up-to-the-minute and complete understanding of the critical legal, business and management issues required to facilitate a winning life sciences transaction.
American Conference Institute's Second Annual conference materials on Pharmaceutical/Biotech Collaborations will bring you thoughtful and targeted commentary from an outstanding faculty of leading in-house biotech and pharmaceutical counsel and expert attorneys with extensive experience in putting together, managing, salvaging and exiting collaborations. They provided practical information and insights on:
- Real life examples of successful deals and insights into how these deals were negotiated and structured
- How to finance and fund a deal today
- New due diligence concerns
- How to structure the deal to protect collective and individual IP rights
- How to form effective co-promotion and co-marketing arrangements
- Successful troubleshooting for collaborations between: established players, biotechs and industry and academia
And much more
This is by far the most comprehensive program of the year on collaborations. Take this opportunity to get the information that you need from those who have mastered "the art of the deal".
Contents & Contributors
MAKING PHARMA AND BIOTECH COLLABORATIONS WORK TO FILL
THE PIPELINE: REAL WORLD CHALLENGES AND REAL WORLD
SOLUTIONS
Richard Smith, Palmer & Dodge
BIOTECH WITH LEADING TECHNOLOGY AND INTERESTING PRODUCT
OPPORTUNITIES!
Dr. Manon M.J. Cox, Protein Sciences Corp.
MAKING PHARMACEUTICAL AND BIOTECH COLLABORATIONS WORK TO
FILL THE PIPELINE: REAL WORLD CHALLENGES AND REAL WORLD
SOLUTIONS
John A. Westwood, PhD, L.E.K. Consulting
STRUCTURING, DRAFTING AND NEGOTIATING PHARMACEUTICAL AND
BIOTECH LICENSES
Adam H. Golden, Kaye Scholer LLP
STRUCTURING THE DEAL: MANAGING PHARMACEUTICAL
COLLABORATION RISKS IN THE CONTRACT
David N. Lawson, Gilead Sciences, Inc.
BUSINESS DEVELOPMENT AND THE PROCESS OF PARTNERING
Deanna M. Petersen, Antigenics
MODEL DUE DILIGENCE CHECKLIST
Maureen A. Rogers, Novartis Consumer Health, Inc.
CAN THIS DEAL BE SAVED?
James P. Kappel, Eli Lilly & Co.
EXIT STRATEGIES
Charles Weiss, Kenyon & Kenyon
THE GOVERNANCE AND MANAGEMENT OF COLLABORATIONS
Ira L. Kotel, Dickstein Shapiro Morin & Oshinsky LLP
David L. Lopez, Discovery Laboratories, Inc.
NEW DUE DILIGENCE CONCERNS
Martin Travers, Sanofi-Sythelabo, Inc.
LICENSING AND INTELLECTUAL PROPERTY CONCERNS RELATIVE TO
PHARMACEUTICAL & BIOTECHNOLOGY COLLABORATIONS
Patricia A. Schreck, Elan Drug Delivery, a division of Elan Corporation, plc.
Michele M. Simkin, Foley & Lardner
BIOTECHNOLOGY-BIOTECHNOLOGY COLLABORATIONS
Jim J. Kovach, Athersys
SPECIAL CONSIDERATIONS FOR CO-PROMOTION AND CO-MARKETING
COLLABORATIONS
Francis V. McNamara, Saul Ewing LLP
Richard Kenny, AstraZeneca Pharmaceuticals LP
COLLABORATIONS BETWEEN ESTABLISHED PLAYERS
Paul A. Thompson, Schering-Plough Corporation
ISSUES UNIQUE TO INDUSTRY/UNIVERSITY COLLABORATIONS
Susan Galli, Ropes & Gray
Jonathan Lourie, Edwards & Angell, LLP
STRUCTURING AND DRAFTING A "WIN-WIN" COLLABORATION
AGREEMENT
William F. Lawrence, Frommer Lawrence & Haug LLP
Thomas J. Kowalski, Frommer Lawrence & Haug LLP
Publication Details